1214265-41-4

Upstream product

• 64-19-7 acetic acid 
• 129321-60-4 5,8-dioxa-10-azadispiro[2.0.44.33]undecane 
• 1214265-36-7 C₁₄H₁₆F₂N₂O₂ 
• 1214265-35-6 3,5-difluoro-4-(7,7-ethylenedioxy-5-azaspiro[2,4]heptan-5-yl)-nitrobenzene 
• 1214265-38-9 (R)-{N-3-[3,5-difluoro-4-(7,7-ethylenedioxy-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methanol 
• 66684-58-0 3,4,5-trifluoronitrobenzene 
• 1214265-39-0 (R)-{N-3-[3,5-difluoro-4-(7,7-ethylenedioxy-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl methanesulfonate 
• 1214265-40-3 (R)-{N-3-[3,5-difluoro-4-(7,7-ethylenedioxy-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl azide 
• 1214265-37-8 N-carbobenzyloxy-[3,5-difluoro-4-(7,7-ethylenedioxy-5-azaspiro[2,4]heptan-5-yl)phenyl]aniline 

Downstream Products

• 1214265-42-5 (S)-N-{{3-[3,5-difluoro-4-(7-oxo-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-28-7 (S)-N-{{3-[3,5-difluoro-4-(7-fluoro-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-27-6 (S)-N-{{3-[3,5-difluoro-4-(7-hydroxy-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-34-5 (S)-N-{{3-[3,5-difluoro-4-(7-amino-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-44-7 C₁₈H₂₀F₂N₆O₃ 
• 1214265-29-8 (S)-N-{{3-[3,5-difluoro-4-(7-hydroxyimino-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-31-2 (S)-N-{{3-[3,5-difluoro-4-(7-hydrazino-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-30-1 (S)-N-{{3-[3,5-difluoro-4-(7-methoxyimino-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-43-6 C₁₉H₂₃F₂N₃O₆S 
• 1214265-32-3 (S)-N-{{3-[3,5-difluoro-4-(7-ethoxyimino-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 

Relevant academic research and scientific papers

NOVEL OXAZOLIDINONE DERIVATIVE WITH DIFLUOROPHENYL MOIETY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND ANTIBIOTIC COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT

Novel oxazolidinone derivatives with a difluorophenyl moiety, represented by Chemical Formula 1, pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient are provided. Exhibiting potent inhibitory activity against Gram-positive bacteria including Haemophilus influenza and Coagulase negative staphylococci and resistant bacteria including vancomycin-resistant en- terococci (VRE), the pharmaceutical composition is useful as an antibiotic.

Novel oxazolidinone derivative with difluorophenyl moiety, pharmaceutically acceptable salt thereof, preparation method thereof and antibiotic composition containing the same as an active ingredient

Novel oxazolidinone derivatives with a difluorophenyl moiety, represented by Chemical Formula 1, pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same as an active ingredient are provided. Exhibiting potent inhibitory activity against Gram-positive bacteria including Haemophilus influenza and Coagulase negative staphylococci and resistant bacteria including vancomycin-resistant enterococci (VRE), the pharmaceutical composition is useful as an antibiotic. (wherein, R is as defined in the specification)